Carnosine Did Not Affect Vascular and Metabolic Outcomes in Patients with Prediabetes and Type 2 Diabetes: A 14-Week Randomized Controlled Trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 49 adults with prediabetes or well-controlled type 2 diabetes
- Dose used in the study
- 2 g carnosine per day
- Duration
- 14 weeks
- What was measured
- Endothelial function (reactive hyperaemia index), arterial stiffness (carotid-femoral pulse wave velocity), blood pressure, heart rate, lipids, liver fibroscan and liver function tests, renal measures.
What the authors reported
Carnosine had no effect on peripheral or central blood pressure, endothelial function, arterial stiffness, lipids, liver or renal outcomes compared with placebo. The authors concluded carnosine did not improve cardiometabolic risk factors in this group and is unlikely to reduce atherosclerotic cardiovascular risk in people with good glycaemic control.
Limits of this study
Small trial (49 participants). Fourteen weeks. Secondary outcomes of a trial whose glucose results were reported separately (Hariharan 2024). Registered NCT02917928. Full text not read.
Source
PubMed 38004228 · doi:10.3390/nu15224835
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.